|

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

RECRUITINGN/ASponsored by Peking University People's Hospital
Actively Recruiting
PhaseN/A
SponsorPeking University People's Hospital
Started2016-08-01
Est. completion2023-12-31
Eligibility
Age18 Years – 45 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05945407

Summary

The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1/2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.

Eligibility

Age: 18 Years – 45 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Stage IA (FIGO 2009) ;
* Pathological diagnosis: endometrial adenocarcinoma G1-G2;
* MRI or ultrasound: tumor limited to endometrium or invading less than 1/2 of myometrium；
* 18 years old ≤ Age ≤ 45 years old;
* With a strong desire for fertility preservation；
* Sign the informed consent.

Exclusion Criteria:

* Complicated with any other malignancy；
* Contraindications to conservative treatment；
* Contraindications to progestin use;
* Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.

Conditions6

CancerCarcinoma, EndometrioidEndometrial Neoplasm MalignantEndometrial Neoplasm Malignant Stage IEndometrial NeoplasmsFertility Preservation

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.